Program
luliconazole
Also written as “Luliconazole Cream 1%”, “SKX-16 (Luliconazole 10% Solution)” and “Luliconazole Solution, 10%”.
Its studies are mostly in Onychomycosis · Tinea Pedis · Tinea, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 30 open or running | phase 4since Feb 19, 2015 | Feb 19, 2015 | none ahead |
| SATO Pharmaceutical | 21 open or running | phase 2since Oct 15, 2026 | Jul 25, 2021 | Sep 23, 2028phase 2 · NCT07929844 |
| Topica Pharmaceuticals | 20 open or running | phase 3since Sep 8, 2011 | Jan 4, 2010 | none ahead |
| Tinea Pharmaceuticals | 10 open or running | phase 2since Mar 25, 2009 | Mar 25, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2009First study: phase 2 study in Tinea PedisNew to Tinea PharmaceuticalsTinea Pharmaceuticals · NCT00869336 · 147 enrolled · United States
- Jan 4, 2010Topica Pharmaceuticals's first study: phase 2 study in OnychomycosisNew to Topica PharmaceuticalsTopica Pharmaceuticals · NCT01044381 · 24 enrolled · United States
- Sep 8, 2011Phase 3 study in OnychomycosisTopica Pharmaceuticals · NCT01431820 · 334 enrolled · United States
- Feb 19, 2015Bausch Health Companies's first study: phase 4 study in Tinea PedisNew to Bausch Health CompaniesBausch Health Companies · NCT02394340 · 20 enrolled · United States
- May 3, 20162 phase 4 studiesBausch Health Companies · NCT02767271, NCT02767947
- Jul 25, 2021SATO Pharmaceutical's first study: phase 1 study in OnychomycosisNew to SATO PharmaceuticalSATO Pharmaceutical · NCT05110638 · 19 enrolled · United States
- Oct 15, 2026Phase 2 study in OnychomycosisPhase 2 reachedSATO Pharmaceutical · NCT07929844 · 204 planned · United States
Ahead
- Sep 23, 2028Primary completion: phase 2 study in OnychomycosisSATO Pharmaceutical · NCT07929844
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07929844Onychomycosis · United States | 2 | Not yet recruiting | SATO Pharmaceutical | Sep 23, 2028 | 204 |
| NCT05110638Onychomycosis · United States | 1 | Completed | SATO Pharmaceutical | May 30, 2022 | 19 |
| NCT02767947Tinea · Dominican Republic, Honduras | 4 | Completed | Bausch Health Companies | Jun 29, 2016 | 75 |
| NCT02767271Tinea Pedis · Dominican Republic, Honduras | 4 | Completed | Bausch Health Companies | Apr 27, 2016 | 30 |
| NCT02394340Tinea Pedis · United States | 4 | Completed | Bausch Health Companies | Apr 1, 2015 | 20 |
| NCT01431820Onychomycosis · United States | 3 | Completed | Topica Pharmaceuticals | Jun 2014 | 334 |
| NCT01044381Onychomycosis · United States | 2 | Completed | Topica Pharmaceuticals | May 2011 | 24 |
| NCT00869336Tinea Pedis · United States | 2 | Completed | Tinea Pharmaceuticals | Sep 2009 | 147 |
How it is read
Names in the registry
- “Luliconazole Cream 1%”, 3 entries
- “SKX-16 (Luliconazole 10% Solution)”, 2 entries
- “Luliconazole Solution, 10%”, 2 entries
- “Luliconazole Cream 1% - 2 wks”, 1 entry
- “Luliconazole Cream 1% - 4 wks”, 1 entry
Conditions, from the studies’ own filings
- Onychomycosis, 4 studies
- Tinea Pedis, 3 studies
- Tinea, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.